ECCO 2024

The quest for predictive markers goes on...

S1P-Modulators from a safety perspective

Real-world data from a H2H-study on Vedolizumab vs.…

Primary sclerosing cholangitis – lessons from a large…

Treatment targets in 2024 - a silent revolution

Cell-based therapies: The end of the story or the…

Finally here: controlled trials in surgery!

A spotlight on the PROFILE study

IL-23 in UC

Ustekinumab first, anti-p19 second?

Next chapter in S1P- and JAK-inhibition

Obefazimod & IL23R-CAR-Tregs - new molecules in focus

Results of the phase II PIZZICATO (ritlecitinib &…

PIZZICATO - new JAKies for crohn's disease

Darvadstrocel for complex perianal fistulas and Crohn’s…

VIVID 1: Mirikizumab in Crohn's Disease

Tregs - a treatment for the future?

VIVID 1: Comparison of mirikizumab with ustekinumab in…

Changing the PROFILE of how we treat CD

Mirikizumab in crohn's disease

Mirikizumab in moderate to severe Crohn’s disease:…

Mirikizumab στη θεραπεία της μέτριας προς βαρειά NC:…

Mirikizumab vs Ustekinumab

Mirikizumab bei Morbus Crohn

VIVID 1- Comparação do Mirikizumab com o Ustecinumab na…

Resultaten van de fase 2 PIZZICATO (ritlecitinib &…

VTX-002 in patients with moderate to severe UC

Mirikizumab in anti-TNF failures with UC

Risankizumab & guselkumab in ulcerative colitis

VTX002 (S1P-modulator) & obefazimod in ulcerative…

Long term outcome of Obefazimod in UC

Leki biologiczne i małocząsteczkowe w terapii…

lange-termijns uitkomst van obefazimod in UC

Risankizumab & Guselkumab bei Colitis Ulcerosa

VTX-002 in pazienti con colite ulcerosa da moderata a…

Still a long road ahead in standards of care in IBD –…

Therapy in transition

Esame di comparabilità tra SP17 e ustekimumab…

Therapie im Umbruch

Changing treatment paradigm in CD

PROFILE: practice-changing results

Should we proactively treat CD-patients having small…

Early intervention in Crohn´s disease therapy

Allogenic mesenchymal stem cells for complex fistula in…

Biomarker for biological loss of response in CD?

Results from the PROFILE-trial

Risultati dallo studio PROFILE

Biomarker for biological loss of response in CD?

PROFILE: Biomarker nicht erfolgreich zur Prädiktion der…

Faut-il traiter les patients avec les lesions de Crohn…

Cambiano i paradigmi di trattamento nelle malattie di…

Injection de cellules souches mesenchimateuses…

Guselkumab & Golimumab have complementary effects when…

Guselkumab & Golimumab ont des effets complémentaires…

Therapy in transition

Use of CAR-Tregs in IBD: preclinical data

Personalized treatment in IBD: reality or hype?

HD-WLE with segmental reinspection is not inferior to…

gepersonaliseerde aanpak van IBD: realiteit of hype?

Therapie im Umbruch

HD-WLE με επανεξέταση των τμημάτων δεν υπολείπεται της…

Utilizzo di cellule CAR Tregs nelle MICI: dati…

Extended mesenterectomy is not superior to mesenteric…

Colectomy and the natural history of PSC – lessons form…

MIRACLE project: Avoidance of protective Ileostomy

No changes to surgical techniques for ileosecal…

Randomised clinical trials finally coming to IBD…

End of the Kono-S legend!

Kolektomia a historia naturalna PSC – czy istnieje…

Los ensayos clínicos aleatorizados llegan a la cirugía…

Η εκτεταμένη εκτομή του μεσεντερίου δεν υπερέχει της…

MIRACLE-Projekt: Verzicht auf protektive Ileostomie

La fin de la legende du Kono-S!

Transcriptomic profiles in patients with UC receiving…

Molekulare Effekte der IL-23p19-Blockade